Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| London South Bank University | OTHER |
| ELAROS 24/7 Limited (UK) | UNKNOWN |
| Servicio De Salud De Castilla La Mancha (Spain) | UNKNOWN |
| IMT School for Advanced Studies Lucca |
Not provided
Not provided
Not provided
Not provided
This is an open, multicentric, interventional, prospective, non-randomized clinical investigation. The first aim of the study is to confirm that MammoWave reaches sensitivity>75% and specificity>90% in breast cancer (BC) detection on 10.000 volunteers undergoing regular screening programs.
MammoWave is a non-CE marked device that uses low-power (1mW) microwaves (1-9 GHz) instead of ionizing radiation (X-ray) for BC screening. MammoWave uses safe low-power radio frequency signals in the microwave band; it is a Class IIa medical device (non-invasive device). The previous generation of MammoWave had obtained the CE mark; in this investigation, the device contains the same hardware and will be used with the same acquisition method as the CE marked device, but additional data processing software will be used.
The 10,000 volunteers undergoing conventional breast screening examination will also undergo the MammoWave exam. The MammoWave results (WSF: breast With Suspicious Finding,i.e. with suspicious lesion, or NSF: No Suspicious Finding, i.e. breast without lesion or with low suspicious lesion) will be checked against the Reference Standard, to be intended as the output of conventional breast examination path (i.e., screening mammogram, integrated with other radiological/histological output when deemed necessary by the responsible Investigator in each site). Reference Standard may be BC+ for the histology-confirmed breast cancer (BI-RADS 6); BC- otherwise (BI-RADS 1, 2, 3).
(NOTE: BIRADS 4 and 5 are only image suspicion criteria: when a biopsy is performed, BIRADS are transformed in 6 (BC+) or 1,2 and 3 (BC-))
This clinical trial is performed within MammoScreen project [1] awarded in the context of HORIZON-MISS-2021-CANCER-02-01. UBT Srl is a partner of a Consortium which comprises (in addition to UBT): Toscana Life Sciences Foundation (Italy); London South Bank University (UK); ELAROS 24/7 Limited (UK); Servicio De Salud De Castilla La Mancha (Spain); Scuola IMT Alti Studi Lucca (Italy); EVITA - Cancro Hereditário (Portugal).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm | Other | All participants perform: conventional breast examination path (i.e., screening mammogram, integrated with other radiological/histological output when deemed necessary by the responsible Investigator in each site) AND MammoWave exam. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MammoWave | Device | Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study. A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts. The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave. When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm. |
| Measure | Description | Time Frame |
|---|---|---|
| MammoWave® sensitivity | MammoWave® sensitivity (percentage of 'true positive' results) while using an optimized classification algorithm. The Reference Standard is intended as the output of conventional breast examination path (i.e. screening mammogram, integrated with other radiological/histological output when deemed necessary by the responsible Investigator). Reference Standard may be: BC+ for the histology-confirmed and classified as BI-RADS 1,2 or 3. | During the procedure |
| MammoWave® specificity | MammoWave® specificity (percentage of 'true negative' results) while using an optimized algorithm. | During the procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Detection rates by type of lesion | Evaluation of the detection rates (sensitivity) according to the type of radiological finding (microcalcification, mass, asymmetry or architectural distortion group), also by breast density (according to BI-RADS ACR classification assigned by the radiologist), and comparison with the other standard screening and diagnostic modalities. | During the baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gianluigi Tiberi | Contact | 0039 3490564302 | gianluigi@ubt-tech.com | |
| Sabatino Tiberi | Contact | s.tiberi@ubt-tech.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IRCCS Policlinico San Martino | Recruiting | Genova | Genova | 16132 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39488412 | Derived | Alvarez Sanchez-Bayuela D, Fernandez Martin J, Tiberi G, Ghavami N, Giovanetti Gonzalez R, Cruz Hernanez LM, Aguilar Angulo PM, Martinez Gomez AD, Rodriguez Sanchez A, Bigotti A, Khalesi B, Pontoriero L, Calabrese M, Tagliafico AS, Romero Castellano C. Microwave imaging for breast cancer screening: protocol for an open, multicentric, interventional, prospective, non-randomised clinical investigation to evaluate cancer detection capabilities of MammoWave system on an asymptomatic population across multiple European countries. BMJ Open. 2024 Nov 2;14(11):e088431. doi: 10.1136/bmjopen-2024-088431. |
| Label | URL |
|---|---|
| \[1\] | View source |
Not provided
Not provided
| OTHER |
| EVITA - Cancro Hereditário (Portugal) | UNKNOWN |
| Fondazione Toscana Life Sciences (Italy) | UNKNOWN |
Clinical Investigation with class IIa medical device
Not provided
Not provided
Not provided
Not provided
|
| Recall rate | Evaluation of MammoWave recalls, also by breast density (according to BI-RADS ACR classification assigned by the radiologist), and comparison with the other standard screening and diagnostic modalities. | During the baseline |
| Positive-predictive value | Evaluation of MammoWave positive predictive value (for the biopsies performed), also by breast density (according to BI-RADS ACR classification assigned by the radiologist), and comparison with the other standard screening and diagnostic modalities. | During the baseline |
| Program screening rate | Program screening rate, calculated as the proportion of women diagnosed with BC in the study population | During the baseline |
| BC detection rates of each by histological type and size of the BC and BI-RADS classification, also by breast density | BC detection rates of each by histological type and size of the BC and BI-RADS classification, also by breast density | During the baseline |
| MammoWave® sensitivity and specificity after retrospective AI adjustment using the data at the end of the study | Evaluation of the improvement in both sensitivity and specificity when retrospectively using AI algorithms for the evaluation of MammoWave® data after its further optimization with all data collected in the participants included in the study. | During the baseline |
| Agreement between different evaluator (i.e. local versus central) | Evaluation of the reproducibility of results comparing the lectures performed at the study centers and the centralized lectures | During the baseline |
| Volunteers' satisfaction questionnaire | Volunteers' satisfaction through a properly designed questionnaire collecting women's issues and plus during the exam with MammoWave® in the language spoken by the women | During the baseline |
| Ospedale San Giovanni Battista - USL Umbria 2 | Recruiting | Foligno | Perugia | 06034 | Italy |
|
| Az. San. Univ. Giuliano Isontina (ASU GI) | Recruiting | Trieste | 34128 | Italy |
|
| Pomeranian Medical University Hospital | Recruiting | Szczecin | Poland |
|
| Champalimaud Foundation | Recruiting | Lisbon | Portugal |
|
| Clínica Dr. Passos Ângelo in Lisbon | Recruiting | Lisbon | Portugal |
|
| Hospital Universitario Reina Sofía- Córdoba | Recruiting | Córdoba | Spain |
|
| Hospital General Universitario Morales Meseguer | Recruiting | Murcia | Spain |
|
| Complejo Hospitalario Universitario de Toledo | Recruiting | Toledo | Spain |
|
| Diagnostic and Interventional Radiology, University Hospital Zurich | Recruiting | Zurich | Switzerland |
|